Mitchell Jones
Chief Medical Officer Palisade Bio
Seminars
Thursday 2nd April 2026
Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
9:00 am
- Highlighting how gut-restricted pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
